COMMUNIQUÉS West-GlobeNewswire

VALNEVA Reports Strong Q1 Results and Continues to Advance Key R&D Programs
17/05/2018
Valneva Reports Strong Q1 Results and Continues to Advance Key R&D Programs Strong sales and EBITDA performance in Q1 2018 Product sales of €28.9 million in Q1 2018, representing 11.5% year on year growth, in line [...]
VALNEVA publie de très bons résultats financiers au premier trimestre, continue d'avancer sur ses programmes R&D clés
17/05/2018
Valneva publie de très bons résultats financiers au premier trimestre, continue d'avancer sur ses programmes R&D clés Forte performance des ventes et de l'EBITDA au T1 2018 Ventes de produits de €28,9 millions au T1 [...]
INNATE PHARMA : Preliminary activity observed of the combination of monalizumab and durvalumab in patients with colorectal cancer
17/05/2018
preliminary DATA from a phase I dose escalation and expansion study of monalizumab and Imfinzi ® (durvalumab) SHOW ANTI-TUMOR activity in COLORECTAL CANCER patients Preliminary activity observed in patients with [...]
INNATE PHARMA : Données préliminaires d'activité de la combinaison monalizumab et durvalumab dans le cancer colorectal
17/05/2018
DES DONN É ES PR É LIMINAIRES D'UN ESSAI DE PHASE I É VALUANT MONALIZUMAB ET IMFINZI® (DURVALUMAB) MONTRENT UNE ACTIVIT É ANTI-TUMORALE CHEZ DES PATIENTS PR É SENTANT UN CANCER COLORECTAL Activité préliminaire observée [...]
Biocartis Group NV: Two Performance Studies on Idylla(TM) MSI Biomarkers Selected for Publication at ASCO Conference
17/05/2018
PRESS RELEASE : 17 May 2018, 07:00 CEST Two Performance Studies on Idylla(TM) MSI Biomarkers Selected for Publication at ASCO Conference Mechelen, Belgium, 17 May 2018 - Biocartis Group NV (the 'Company' or 'Biocartis [...]
argenx to Present at Upcoming Investor Conferences
17/05/2018
May 17, 2018 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment [...]
Endocyte Announces Presentation of Phase 2 Data from Investigator-Initiated Prostate Cancer Trial of 177Lu-PSMA-617 at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
17/05/2018
– PSA response rates in additional 20 mCRPC patients enrolled at Peter MacCallum Cancer Centre higher than previously reported for first group of 30 patients – – Company to host and webcast investor event featuring [...]
Correction: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018
16/05/2018
Company Release no. 12/2018 To: Nasdaq Copenhagen A/S Copenhagen, Denmark, 16 May 2018 Correction: Veloxis Pharmaceuticals Announces Financial Results for the First Three Months of 2018 Correction: In the company [...]
TESARO Announces Presentations of Abstracts at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
16/05/2018
Investor briefing to be webcast from Chicago on Monday, June 4, 2018 at 6:15PM CT WALTHAM, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ: TSRO ), an oncology-focused biopharmaceutical company, today [...]
Dynavax to Present New Data for SD-101 in Combination with KEYTRUDA® (pembrolizumab) at the 2018 American Society for Clinical Oncology Annual Meeting
16/05/2018
Abstract Data Show Overall Response Rate of 60% in 25 Advanced Melanoma Patients Naïve to Anti-PD-1 Therapy Poster Presentation to Include Data from a Total of over 50 Patients and Will Compare SD-101 at Two Dose Levels [...]
G1 Therapeutics to Present Phase 1b Data on G1T38 in Combination with Faslodex for Treatment of Breast Cancer at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
16/05/2018
RESEARCH TRIANGLE PARK, N.C., May 16, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that preliminary data from its Phase 1b/2a clinical trial of G1T38 [...]
Purepoint Uranium Issues Stock Options
16/05/2018
TORONTO, May 16, 2018 (GLOBE NEWSWIRE) -- Purepoint Uranium Group Inc. (the “ Company ” or “ Purepoint ”) (TSX:PTU.V) today approved the issuance of a total of 3,150,000 options to its Board of Directors, management and [...]
CytomX Therapeutics Announces Presentations at 2018 ASCO Annual Meeting
16/05/2018
- Preliminary first-in-human data to be presented from PROCLAIM-CX-072 trial of a PD-L1 Probody therapeutic as a monotherapy and in combination with ipilimumab - SOUTH SAN FRANCISCO, Calif., May 16, 2018 (GLOBE NEWSWIRE [...]
Agios to Present New Clinical Data from its IDH Programs at ASCO
16/05/2018
– Updated Data From Ivosidenib Phase 1 Expansion in IDH1m R/R AML and the First Data from the AG-881 Phase 1 Study in IDHm Glioma to be Highlighted in Oral Presentations – – New Data From Fully Enrolled Ivosidenib Arm [...]
Bavarian Nordic Announces Acceptance of Abstracts and Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
16/05/2018
COPENHAGEN, Denmark, May 16, 2018 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today announced the acceptance of 4 poster presentations and one podium presentation at the American Society of Clinical Oncology (ASCO) [...]
Celldex Announces Presentations at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
16/05/2018
HAMPTON, N.J., May 16, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ: CLDX ) announced today that two abstracts will be presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting [...]
Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting
16/05/2018
ICONIC Target Enrollment Met Across Four Combination Cohorts Company to Host Investor Event and Live Webcast on Monday, June 4 CAMBRIDGE, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE [...]
Immunomedics Announces Promising Data of Sacituzumab Govitecan in Estrogen Receptor-Positive Metastatic Breast Cancer
16/05/2018
Sacituzumab Govitecan Produced Overall Response Rate of 31 Percent in Patients Post Endocrine Treatment with a Manageable Safety Profile Full Data will be Reported in Oral Presentation at 2018 American Society of [...]
Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting
16/05/2018
PHILADELPHIA and OXFORD, U.K., May 16, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP ), a leader in T-cell therapy to treat cancer, will release updated data from ongoing clinical studies at the [...]

Pages